ARCA biopharma
Oruka Therapeutics is dedicated to developing novel biologics aimed at providing freedom from chronic skin diseases such as plaque psoriasis and psoriatic arthritis. Their mission is to improve patient experiences by advancing potentially best-in-class monoclonal antibodies that deliver higher rates of complete disease clearance with minimal dosing.
Industries
Nr. of Employees
small (1-50)
ARCA biopharma
203 Crescent Street Building 21, Suite 203, Waltham, MA 02453
Patents
Products
Clinical‑stage antibody targeting IL‑23p19
A monoclonal antibody program designed to inhibit the p19 subunit of interleukin‑23, engineered for extended circulation and the potential for infrequent dosing in psoriasis.
IND‑enabling antibody targeting IL‑17A/F
A development-stage monoclonal antibody program designed to inhibit interleukin‑17A and interleukin‑17F for inflammatory diseases, optimized for extended circulation and potential infrequent dosing.
Early‑discovery antibody candidates
Discovery-stage antibody programs and undisclosed candidates at early stages of development.
Sequential combination regimen development
Development of sequential combination regimens designed to provide rapid responses followed by an ideal maintenance profile using multiple antibody agents.
Clinical‑stage antibody targeting IL‑23p19
A monoclonal antibody program designed to inhibit the p19 subunit of interleukin‑23, engineered for extended circulation and the potential for infrequent dosing in psoriasis.
IND‑enabling antibody targeting IL‑17A/F
A development-stage monoclonal antibody program designed to inhibit interleukin‑17A and interleukin‑17F for inflammatory diseases, optimized for extended circulation and potential infrequent dosing.
Early‑discovery antibody candidates
Discovery-stage antibody programs and undisclosed candidates at early stages of development.
Sequential combination regimen development
Development of sequential combination regimens designed to provide rapid responses followed by an ideal maintenance profile using multiple antibody agents.
Services
Co-development and collaboration with external antibody discovery and engineering organizations to advance discovery-stage candidates toward clinical development.
Co-development and collaboration with external antibody discovery and engineering organizations to advance discovery-stage candidates toward clinical development.
Expertise Areas
- Antibody engineering and discovery
- Biologics development (discovery to clinical)
- Preclinical and nonclinical development
- Clinical trial program execution
Key Technologies
- Monoclonal antibody therapeutics
- Antibody engineering
- Half‑life extension technologies
- Affinity maturation and specificity engineering
News & Updates
Announcement of Laura Sandler's promotion to COO at Oruka Therapeutics.
Announcement of Laura Sandler's promotion to COO at Oruka Therapeutics.